Manuel Hidalgo Selected Research

temsirolimus

8/2012	Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
6/2010	Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
6/2009	[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
11/2007	A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).
2/2007	Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays.
10/2006	A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
8/2005	Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
2/2005	Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
3/2004	Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
8/2003	Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manuel Hidalgo Research Topics

Disease

166	Neoplasms (Cancer) 11/2022 - 01/2002
70	Pancreatic Neoplasms (Pancreatic Cancer) 11/2022 - 11/2002
31	Adenocarcinoma 02/2022 - 11/2002
24	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 03/2003
11	Disease Progression 01/2021 - 08/2003
11	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 09/2002
8	Carcinoma (Carcinomatosis) 11/2021 - 01/2003
8	Breast Neoplasms (Breast Cancer) 01/2020 - 08/2003
7	Neoplasm Metastasis (Metastasis) 02/2022 - 09/2002
7	Lung Neoplasms (Lung Cancer) 01/2019 - 02/2002
7	Diarrhea 12/2006 - 01/2004
6	Neutropenia 01/2021 - 09/2008
6	Carcinogenesis 01/2021 - 01/2003
6	Exanthema (Rash) 06/2010 - 01/2004
4	Fatigue 01/2019 - 05/2009
4	Melanoma (Melanoma, Malignant) 09/2017 - 07/2002
4	Mucositis 12/2010 - 10/2006
3	Squamous Cell Carcinoma of Head and Neck 01/2019 - 01/2004
3	Nausea 01/2019 - 10/2006
3	Asthenia 01/2019 - 10/2006
3	Cholangiocarcinoma 08/2015 - 11/2004
3	Colonic Neoplasms (Colon Cancer) 04/2015 - 08/2006
3	Biliary Tract Neoplasms (Biliary Tract Cancer) 12/2005 - 11/2004
3	Renal Cell Carcinoma (Grawitz Tumor) 02/2005 - 08/2003
2	Infections 01/2021 - 10/2013
2	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 11/2002
2	Glioblastoma (Glioblastoma Multiforme) 01/2019 - 08/2005
2	Stomatitis 01/2019 - 10/2006
2	Hyperglycemia 01/2019 - 09/2008
2	Thrombocytopenia (Thrombopenia) 01/2019 - 08/2014
2	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 03/2016
2	Necrosis 01/2016 - 09/2012
2	Febrile Neutropenia 01/2016 - 07/2006
2	Ovarian Neoplasms (Ovarian Cancer) 08/2015 - 12/2008
2	Anemia 06/2015 - 09/2008

Drug/Important Bio-Agent (IBA)

31	Gemcitabine FDA Link 01/2021 - 04/2006
30	Pharmaceutical PreparationsIBA 01/2022 - 07/2003
27	ErbB Receptors (EGF Receptor)IBA 01/2018 - 06/2003
19	Proteins (Proteins, Gene)FDA Link 11/2020 - 06/2003
19	Phosphotransferases (Kinase)IBA 01/2020 - 09/2002
18	Biomarkers (Surrogate Marker)IBA 02/2021 - 01/2003
18	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2013 - 07/2003
17	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 12/2004
11	Tyrosine Kinase InhibitorsIBA 01/2018 - 01/2004
11	Cetuximab (Erbitux)FDA Link 01/2018 - 04/2005
11	temsirolimus FDA Link 08/2012 - 11/2002
10	Biological ProductsIBA 01/2014 - 11/2002
10	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2013 - 12/2004
10	Gefitinib (Iressa)FDA Link 01/2013 - 05/2005
9	Sirolimus (Rapamycin)FDA Link 12/2014 - 11/2002
9	TOR Serine-Threonine KinasesIBA 06/2010 - 08/2003
7	Irinotecan (Camptosar)FDA LinkGeneric 01/2021 - 03/2003
7	130-nm albumin-bound paclitaxelIBA 01/2019 - 12/2011
7	Transaminases (Aminotransferases)IBA 01/2019 - 10/2006
6	Antineoplastic Agents (Antineoplastics)IBA 11/2021 - 06/2006
6	LigandsIBA 01/2021 - 10/2004
6	Capecitabine (Xeloda)FDA Link 01/2018 - 09/2008
6	EnzymesIBA 08/2015 - 07/2002
5	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 03/2003
5	Bevacizumab (Avastin)FDA Link 01/2019 - 11/2007
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2016 - 12/2006
4	Leucovorin (Folinic Acid)FDA Link 01/2021 - 03/2003
4	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2003
4	Albumin-Bound Paclitaxel FDA Link 01/2019 - 10/2013
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2018 - 11/2006
4	Carboplatin (JM8)FDA LinkGeneric 01/2018 - 12/2006
4	Mitogen-Activated Protein KinasesIBA 01/2017 - 07/2006
3	AntigensIBA 11/2021 - 01/2003
3	AntibodiesIBA 11/2021 - 08/2010
3	EstersIBA 11/2021 - 11/2002
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2021 - 01/2018
3	pembrolizumabIBA 01/2021 - 01/2020
3	Docetaxel (Taxotere)FDA Link 01/2019 - 07/2006
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 01/2003
3	Small Interfering RNA (siRNA)IBA 11/2018 - 04/2005
3	Thymidylate SynthaseIBA 01/2016 - 10/2011
3	Therapeutic UsesIBA 01/2016 - 01/2013
3	Mitomycin (Mitomycin-C)FDA LinkGeneric 12/2014 - 04/2006
3	Messenger RNA (mRNA)IBA 11/2009 - 12/2004
3	TrabectedinIBA 05/2009 - 01/2002
3	Growth Factor ReceptorsIBA 08/2007 - 01/2003
2	Transcription Factors (Transcription Factor)IBA 02/2022 - 01/2003
2	Angiopoietin-2IBA 02/2021 - 01/2018
2	vanucizumabIBA 02/2021 - 01/2018
2	CollagenIBA 01/2019 - 01/2005
2	AlbuminsIBA 01/2019 - 10/2013
2	OligonucleotidesIBA 01/2018 - 11/2009
2	MicroRNAs (MicroRNA)IBA 01/2018 - 11/2009
2	Cell-Free Nucleic AcidsIBA 01/2018 - 05/2017
2	MEHD7945AIBA 01/2018 - 06/2015
2	Chloroquine (Aralen)FDA LinkGeneric 09/2017 - 07/2014
2	Metformin (Glucophage)FDA LinkGeneric 09/2017 - 01/2013
2	Somatomedin Receptors (Somatomedin Receptor)IBA 03/2017 - 01/2004
2	PlatinumIBA 01/2017 - 02/2002
2	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 06/2015 - 08/2003

Therapy/Procedure

67	Therapeutics 07/2022 - 02/2002
38	Drug Therapy (Chemotherapy) 07/2022 - 01/2002
5	Immunotherapy 11/2022 - 01/2020
5	Radiotherapy 07/2013 - 09/2002
3	Precision Medicine 01/2017 - 05/2012